Knowthestock.com
AXDX - Accelerate Diagnostics Inc
Compare

Sell

Weak Growth●Earnings/Profit is Negative

30%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 20.09%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -700.47%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 11.76
Debt Ratio is 1.67
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.06
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Accelerate Diagnostics Inc (AXDX) - http://acceleratediagnostics.com/
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
Exchange - NASDAQ CAPITAL MARKET
Industry - Analytical Laboratory Instrument Manufacturing
Sector - Manufacturing
CEO - John Phillips
    Close
Cookie Policy
Disclaimer
Privacy Policy
Terms of Service
About Us
Contact Us
Help
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.